World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Professor John Axford - Professor of Rheumatology (MD., DSc, F.R.C.P.)

Professor John Axford studied medicine at University College, London in 1989. He was chosen as a Fulbright Scholar and performed research in various areas of immunology both at the Middlesex Hospital Medical School, and Tufts University, USA. In 1990, Professor Axford completed his research thesis in arthritic diseases and in 1991 was awarded his M.D. with a Specialist Accreditation in Rheumatology and Immunology.

He has lectured extensively throughout the United States, the United Kingdom, Europe, Australia, and Asia and has authored or co-authored over 80 published peer-reviewed scientific papers, over 128 published abstracts and letters, and 18 medical textbooks. Professor Axford is a past section President of the Royal Society of Medicine and currently serves on the Editorial Boards of three medical journals and on numerous medical and health related committees. He is also Editor of the Undergraduate textbook 'Medicine'.

At present, Professor Axford is the Professor of Clinical Rheumatology and the Director of Sir Joseph Hotung Centre for Musculoskeletal Disorders for St George's University of London, where he directs the provision of clinical and basic scientific research, clinical care and both undergraduate and postgraduate education. He joined St George's University of London in 1990 and was appointed Chair of Clinical Rheumatology in 2005.

Currently, Professor Axford is serving as the Principal Investigator for 2 three-year clinical trials funded by St. George's University of London and NHS Hospital.

Back to experts

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more

Dr Jorg Taubel, CEO of Richmond Pharmacology, features on the PM Live website, discussing clincial trials and COVID-19

August 11, 2020
Dr Jorg Taubel discusses some of the steps taken at Richmond Pharmacology to ensure clinical trials can continue to operate at a high standard throughout the COVID-19 pandemic.
Read more